Rupp, M.; Fanton-Aita, F.; Snow, S.; Wheatley-Price, P.; Melosky, B.; Juergens, R.A.; Chu, Q.; Blais, N.; Banerji, S.; Ng, R.;
et al. Lorlatinib Effectiveness and Quality-of-Life in Patients with ALK-Positive NSCLC Who Had Failed Second-Generation ALK Inhibitors: Canadian Real-World Experience. Curr. Oncol. 2023, 30, 6559-6574.
https://doi.org/10.3390/curroncol30070481
AMA Style
Rupp M, Fanton-Aita F, Snow S, Wheatley-Price P, Melosky B, Juergens RA, Chu Q, Blais N, Banerji S, Ng R,
et al. Lorlatinib Effectiveness and Quality-of-Life in Patients with ALK-Positive NSCLC Who Had Failed Second-Generation ALK Inhibitors: Canadian Real-World Experience. Current Oncology. 2023; 30(7):6559-6574.
https://doi.org/10.3390/curroncol30070481
Chicago/Turabian Style
Rupp, Martin, Fiorella Fanton-Aita, Stephanie Snow, Paul Wheatley-Price, Barbara Melosky, Rosalyn A. Juergens, Quincy Chu, Normand Blais, Shantanu Banerji, Ryan Ng,
and et al. 2023. "Lorlatinib Effectiveness and Quality-of-Life in Patients with ALK-Positive NSCLC Who Had Failed Second-Generation ALK Inhibitors: Canadian Real-World Experience" Current Oncology 30, no. 7: 6559-6574.
https://doi.org/10.3390/curroncol30070481
APA Style
Rupp, M., Fanton-Aita, F., Snow, S., Wheatley-Price, P., Melosky, B., Juergens, R. A., Chu, Q., Blais, N., Banerji, S., Ng, R., Khoudigian, S., Sharma, A., On, P. V., & Liu, G.
(2023). Lorlatinib Effectiveness and Quality-of-Life in Patients with ALK-Positive NSCLC Who Had Failed Second-Generation ALK Inhibitors: Canadian Real-World Experience. Current Oncology, 30(7), 6559-6574.
https://doi.org/10.3390/curroncol30070481